Patients with hematological malignancies are at risk of severe COVID-19 and candidate to priority vaccination policies, preferably with a mRNA vaccine. In light of ethical considerations and strict indications of Health Authorities (HA), also patients with ongoing lymphodepleting therapy underwent vaccination. In Italy, the national plan against COVID-19 required to proceed as soon as possible with the vaccination of hematological patients in treatment with immunosuppressive or myelosuppressive drugs or within six months from the end of such treatment, and of stem cell transplanted patients after three months from transplant.

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas / Marchesi, F.; Pimpinelli, F.; Giannarelli, D.; Ronchetti, L.; Papa, E.; Falcucci, P.; Pontone, M.; Di Domenico, E. G.; di Martino, S.; Laquintana, V.; Mandoj, C.; Conti, L.; Cordone, I.; La Malfa, A.; Viggiani, C.; Renzi, D.; Palombi, F.; Romano, A.; Pisani, F.; Gumenyuk, S.; Di Bella, O.; Vujovic, B.; Morrone, A.; Ciliberto, G.; Ensoli, F.; Mengarelli, A.. - In: LEUKEMIA. - ISSN 0887-6924. - 36:2(2022), pp. 588-590. [10.1038/s41375-021-01418-8]

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas

Marchesi F.;Pimpinelli F.;Pontone M.;Di Domenico E. G.;Laquintana V.;La Malfa A.;Viggiani C.;Di Bella O.;Ensoli F.;
2022

Abstract

Patients with hematological malignancies are at risk of severe COVID-19 and candidate to priority vaccination policies, preferably with a mRNA vaccine. In light of ethical considerations and strict indications of Health Authorities (HA), also patients with ongoing lymphodepleting therapy underwent vaccination. In Italy, the national plan against COVID-19 required to proceed as soon as possible with the vaccination of hematological patients in treatment with immunosuppressive or myelosuppressive drugs or within six months from the end of such treatment, and of stem cell transplanted patients after three months from transplant.
2022
Aged; aged 80 and over; antibodies, monoclonal; antigens, CD20; BNT162 vaccine; COVID-19; female; follow-up studies; humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; male; prognosis; SARS-CoV-2
01 Pubblicazione su rivista::01a Articolo in rivista
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas / Marchesi, F.; Pimpinelli, F.; Giannarelli, D.; Ronchetti, L.; Papa, E.; Falcucci, P.; Pontone, M.; Di Domenico, E. G.; di Martino, S.; Laquintana, V.; Mandoj, C.; Conti, L.; Cordone, I.; La Malfa, A.; Viggiani, C.; Renzi, D.; Palombi, F.; Romano, A.; Pisani, F.; Gumenyuk, S.; Di Bella, O.; Vujovic, B.; Morrone, A.; Ciliberto, G.; Ensoli, F.; Mengarelli, A.. - In: LEUKEMIA. - ISSN 0887-6924. - 36:2(2022), pp. 588-590. [10.1038/s41375-021-01418-8]
File allegati a questo prodotto
File Dimensione Formato  
Marchesi_Impact_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 455.93 kB
Formato Adobe PDF
455.93 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1630488
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 18
social impact